Dr. Daniel McFarland on Building Programs to Prevent Burnout and Suicide in Oncology Providers

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Cancer Network spoke with Daniel McFarland, DO, of Memorial Sloan Kettering Cancer Center, about building programs to prevent burnout and suicide in oncology providers.

Cancer Network spoke with Daniel McFarland, DO, of Memorial Sloan Kettering Cancer Center, about building programs to prevent burnout and suicide in oncology providers.

Recent Videos
Less lymphocyte depletion with twice-daily radiotherapy warrants further assessment to optimize the synergistic effect of radiotherapy and immunotherapy.
Twice-daily thoracic radiotherapy appeared to confer less leukocyte and lymphocyte depletion compared with once-daily radiation in LS-SCLC.
The clinical adoption of twice-daily accelerated radiotherapy has been limited in North America despite improved outcomes, according to Bin Gui, MD.
Patients with high-risk markers may especially benefit from the addition of daratumumab to lenalidomide as maintenance therapy for NDMM.
Related Content
Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.

Unraveling The Benefits of Twice-Daily Chemoradiotherapy in LS-SCLC

Russ Conroy
October 3rd 2025
Article

Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

In the analysis comparing D-VRd with other regimens for MRD-negative CR rate, there was an 81% probability that it was favorable vs Isa-VRd.

Which Therapy Has the Best Efficacy in Transplant-Ineligible NDMM?

Tim Cortese
October 1st 2025
Article

D-VRd had a 72% chance of providing superior PFS outcomes vs isatuximab plus VRd in patients with transplant-ineligible NDMM.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Overall urinary toxicity was not significantly improved with SBRT vs moderately hypofractionated IMRT.

SBRT Reduces Bowel Toxicity vs IMRT in Intermediate-Risk Prostate Cancer

Tim Cortese
September 30th 2025
Article

SBRT achieved a 5-year DFS of 89% vs 92% with moderately hypofractionated IMRT in patients with intermediate risk prostate cancer.

Long-term data from the STARS trial affirm stereotactic radiation as a strong alternative to surgery for patients with operable stage I NSCLC.

Radiation Shows Similar 10-Year Outcomes Vs Surgery in Early-Stage NSCLC

Russ Conroy
September 30th 2025
Article

Long-term data from the STARS trial affirm stereotactic radiation as a strong alternative to surgery for patients with operable stage I NSCLC.